In molecular diagnostics, the focus will increasingly shift away from setting out a rigid roadmap and towards building integrated, distributed and manageable architectures. This analysis examines five key structural trends in the sector and how Helyx can interpret them from an industrial perspective.

Molecular diagnostics is evolving from a specialist laboratory function into a distributed, connected infrastructure that is integrated into clinical pathways. This article analyses the key trends – decentralisation, AI, personalised medicine, the cloud, accessibility and regulation – and examines the future of the sector through the Helyx One Group – Three Divisions model.

Automation and AI are transforming decentralised molecular diagnostics: portable qPCR, cloud technology, automated quality control and AI/ML algorithms are making workflows faster, more traceable and more scalable. The article examines the benefits, KPIs, governance and the role of the Hyris Division within the Helyx Industries model.

The gut microbiota is a key area for personalised nutrition, but its application requires robust methods, carefully selected biomarkers and cautious interpretation. The article examines the complementary roles of qPCR and NGS, as well as the B2B/OEM potential of Helyx Industries S.p.A. in the nutraceutical sector.